FWM
TTPH

Focused Wealth Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Focused Wealth Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-952
Closed -$9K – 810
2019
Q2 		$9K Buy
+952
New +$17.5K ﹤0.01% 536

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Focused Wealth Management's TTPH Position: Q3 2019 in Review

Focused Wealth Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 952 shares — an estimated $9K sold.

Focused Wealth Management first reported a position in TTPH in Q2 2019 and held it in 1 quarter. The position peaked at $9K in Q2 2019. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Focused Wealth Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Focused Wealth Management sold 952 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $9K.
  • Focused Wealth Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Focused Wealth Management's Tetraphase Pharmaceuticals, Inc. position peaked at $9K in Q2 2019.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Focused Wealth Management's 13F filing for Q3 2019, filed 6 Nov 2019.